

Thyroid cancer Committee meeting 12

Date: 4/11/21 10:00-16:00

Location: Virtual meeting

Minutes: Confirmed

Committee members present:		
Richard Grünewald [RG] – Chair		(Present for notes 1 – 9)
Jeremy Davis [JD] – Topic advisor		(Present for notes 1 – 9)
John Buscombe [JB]		(Present for notes 1 – 9)
Preetha Chengot [PC]		(Present for notes 1 – 9)
Neil Cozens [NC]		(Present for notes 1 – 9)
Fiona Eatock [FE]		(Present for notes 4 – 9)
Steve Hyer [SHY]		(Present for notes 1 – 9)
Jessica Lishak [JL]		(Present for notes 1 – 9)
Kate Newbold [KN]		(Present for notes 1 – 9)
Sonja Hoy [SH]		(Present for notes 1 – 9)
Anh Tran [AT]		(Present for notes 1 – 9)
Nicholas Reed [NR]		(Present for notes 1 – 9)

In attendance:		
Carlos Sharpin [CS]	Guideline Lead	(Present for notes 1 – 9)
Catrina Charlton	NICE Guideline Commissioning Manager	(Present for notes 1 – 5, 7 – 9)
Mark Perry [MP]	Senior Research Fellow	(Present for notes 1 – 9)
Alfredo Mariani [AM]	Health Economist	(Present for notes 1 – 9)
Tamara Diaz [TD]	Project Manager	(Present for notes 1 – 9)

Apologies:	
Kate Farnell [KF]	Lay Member
Iain Nixon	Consultant ENT, Head and Neck Surgeon, NHS Lothian
Lina Gulhane [LG]	Head of Information Specialists

1. Welcome and objectives for the meeting

The Chair welcomed the Committee members and attendees to the twelfth meeting on Thyroid cancer. The Committee members and attendees introduced themselves.

The Chair outlined the objectives of the meeting, which included:

- Radioisotope scans
- Thyroid antibody blood tests and serum calcitonin
- Measuring thyroglobulin and thyroglobulin antibodies post thyroidectomy and RAI

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matters under discussion were radioisotope scans, thyroid antibody blood tests and serum calcitonin and measuring thyroglobulin and thyroglobulin antibodies post thyroidectomy and RAI.

A new declaration was received from JB.

Name	Job title, organisation	Declarations of Interest, date declared	Type of interest	Decision taken
John Buscombe	Consultant Physician in Nuclear Medicine, Barts Health	Have been asked to give a talk by Eisai pharmaceuticals about the role of nuclear medicine in differentiated thyroid cancer to their oncology sales team. The talk will be limited to discussing radioiodine and PET imaging Eisai do not make or sell anything which is used in radioiodine or PET. I will be paid for the lecture. 23 November 2021	Specific. Eisai do not sell anything related to radioiodine or PET and committee member will not discuss the content of the guideline.	Declare and participate.

The Chair and a senior member of the Developer's team noted that the interests previously declared did not prevent the attendees from fully participating in the

meeting.
3. Evidence review: Radioisotope scans
MP presented the clinical evidence for radioisotope scans. AM presented the health economic evidence. The GC drafted recommendations.
4. Evidence review: Thyroid antibody blood tests and serum calcitonin
BV presented the clinical evidence for thyroid antibody blood tests and serum calcitonin. AM presented the health economic evidence. The GC drafted recommendations.
5. Evidence review: Measuring thyroglobulin and thyroglobulin antibodies post thyroidectomy and RAI
MP presented the evidence for measuring thyroglobulin and thyroglobulin antibodies post thyroidectomy and RAI. The GC drafted recommendations.
6. Health economic plan
AM provided an update on the health economic plan and asked for volunteers to join the health economics subgroup.
7. Recommendations: What information, education and support do people with suspected and confirmed thyroid cancer and their families and carers need?
CS presented the edited recommendations for What information, education and support do people with suspected and confirmed thyroid cancer and their families and carers need? The GC provided feedback.
8. Chapter introductions
CS presented the chapter introductions and suggested writers to the GC.
9. Any other business
MP presented some changes to the preventing the risk of recurrence protocol. The GC agreed to change 'normal' to 'standard'. The GC agreed to add an extra sentence to the review question.

Date of next meeting:

10 December 2021

Location of next meeting: Virtual meeting